Skip to main content
Retension Pharmaceuticals, Inc. (RTSN)
NASDAQ: RTSN · Real-Time Price · USD
12.15
+0.13 (1.08%)
Nov 11, 2026, 4:00 PM EST - Market closed

Retension Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Cash & Equivalents
13.4918.98.196.33
Cash & Short-Term Investments
13.4918.98.196.33
Cash Growth
-130.91%29.40%-
Prepaid Expenses
2.632.540.18-
Total Current Assets
16.1321.458.376.33
Total Assets
16.1321.458.376.33

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Accounts Payable
2.790.780.190.02
Accrued Expenses
0.080.140.080.03
Other Current Liabilities
--0.010.11
Total Current Liabilities
2.880.910.280.17
Total Liabilities
2.880.910.280.17

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Common Stock
0000
Additional Paid-In Capital
0.920.530.29-
Retained Earnings
-15.84-8.32-2.01-0.1
Total Common Equity
-14.92-7.78-1.73-0.1
Shareholders' Equity
13.2520.538.096.15
Total Liabilities & Equity
16.1321.458.376.33

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Net Cash (Debt)
13.4918.98.196.33
Net Cash Growth
-130.91%29.40%-
Net Cash Per Share
16.7423.4810.177.86
Filing Date Shares Outstanding
0.810.810.810.81
Total Common Shares Outstanding
0.810.810.810.81
Working Capital
13.2520.538.096.15
Book Value Per Share
-18.48-9.64-2.14-0.13
Tangible Book Value
-14.92-7.78-1.73-0.1
Tangible Book Value Per Share
-18.48-9.64-2.14-0.13
SEC Filings: 10-K · 10-Q